Difference between revisions of "Fluoxetine-moclobemide"
From Psychiatrienet
| Line 5: | Line 5: | ||
{{stopFluoxetine1}} | {{stopFluoxetine1}} | ||
| start = | | start = | ||
| − | * '''Day | + | * '''Day 1-28:''' a wash-out period of four weeks is necessary. |
| − | * '''Day | + | * '''Day 29:''' start moclobemide in a normal dosage of 300 mg/day, if necessary increase dose with 25% (up to 50%) of the target dose every 3 days. |
| caveat = | | caveat = | ||
* Occurrence of serotonin syndrome is reported when a wash-out period (of four weeks) is not considered. | * Occurrence of serotonin syndrome is reported when a wash-out period (of four weeks) is not considered. | ||
Revision as of 14:32, 21 October 2015
| ||||||||||||||||||||||
| ||||||||||||||||||||||
Switch medication from fluoxetine to moclobemide.[1] [2]
Stop fluoxetine - Before day 1: reduce dosage of fluoxetine with about 20 mg per week.
- Day 1: when a dosage of 20 mg/day is reached, stop fluoxetine.
Start moclobemide- Day 1-28: a wash-out period of four weeks is necessary.
- Day 29: start moclobemide in a normal dosage of 300 mg/day, if necessary increase dose with 25% (up to 50%) of the target dose every 3 days.
Cave- Occurrence of serotonin syndrome is reported when a wash-out period (of four weeks) is not considered.
More information- The pharmacologically active metabolite desmethylfluoxetine has a half-life of about 1 week.
- ↑ Switches are based on literature references on this page and expert opinions of the authors. The authors have used pharmacokinetic and receptor affinity properties to determine the switch schedules
- ↑ Stahl, S. M. (2013). Stahl's essential psychopharmacology: Neuroscientific basis and practical applications (4th ed.). Cambridge University Press.
The editors of psychiatrienet.nl take the greatest care to provide up-to-date and accurate information on this site. Nevertheless, mistakes and omissions cannot be entirely excluded. No rights devolve from the information provided. The editors and other providers of information to this site accept no responsibility for the content of this site or for the information provided therein; neither do they accept responsibility for possible damages which may derive from the use of the information on this site or from the linked sites. The editorial board accepts no responsibility for the content of the (linked) sites, for access to them, or for the products and services on these sites, nor for the occurrence of errors, viruses, and/or disruptions in service.
